167 related articles for article (PubMed ID: 10633472)
1. Extraskeletal problems and amyloid.
Drüeke TB
Kidney Int Suppl; 1999 Dec; 73():S89-93. PubMed ID: 10633472
[TBL] [Abstract][Full Text] [Related]
2. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis.
Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF
Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467
[TBL] [Abstract][Full Text] [Related]
3. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y
Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
[TBL] [Abstract][Full Text] [Related]
4. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.
Miyata T; Inagi R; Iida Y; Sato M; Yamada N; Oda O; Maeda K; Seo H
J Clin Invest; 1994 Feb; 93(2):521-8. PubMed ID: 8113390
[TBL] [Abstract][Full Text] [Related]
5. Beta2-microglobulin and amyloidosis.
Drüeke TB
Nephrol Dial Transplant; 2000; 15 Suppl 1():17-24. PubMed ID: 10737162
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and management of dialysis-related amyloid bone disease.
Nangaku M; Miyata T; Kurokawa K
Am J Med Sci; 1999 Jun; 317(6):410-5. PubMed ID: 10372842
[TBL] [Abstract][Full Text] [Related]
7. Beta-2-microglobulin-associated amyloidosis in chronic hemodialysis patients with carpal tunnel syndrome.
Ullian ME; Hammond WS; Alfrey AC; Schultz A; Molitoris BA
Medicine (Baltimore); 1989 Mar; 68(2):107-15. PubMed ID: 2646507
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis.
Miyata T; Inagi R; Kurokawa K
Miner Electrolyte Metab; 1999; 25(1-2):114-7. PubMed ID: 10207272
[TBL] [Abstract][Full Text] [Related]
9. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum.
Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y
Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931
[TBL] [Abstract][Full Text] [Related]
10. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.
Miyata T; Oda O; Inagi R; Iida Y; Araki N; Yamada N; Horiuchi S; Taniguchi N; Maeda K; Kinoshita T
J Clin Invest; 1993 Sep; 92(3):1243-52. PubMed ID: 8376584
[TBL] [Abstract][Full Text] [Related]
11. Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis.
Iida Y; Miyata T; Inagi R; Sugiyama S; Maeda K
Biochem Biophys Res Commun; 1994 Jun; 201(3):1235-41. PubMed ID: 8024566
[TBL] [Abstract][Full Text] [Related]
12. Serum beta 2-microglobulin concentration in dialysis patients: importance of intrinsic renal function.
McCarthy JT; Williams AW; Johnson WJ
J Lab Clin Med; 1994 Apr; 123(4):495-505. PubMed ID: 8144998
[TBL] [Abstract][Full Text] [Related]
13. Dialysis related amyloidosis: a disease of chronic retention and inflammation?
Floege J; Schäffer J; Koch KM; Shaldon S
Kidney Int Suppl; 1992 Oct; 38():S78-85. PubMed ID: 1405384
[TBL] [Abstract][Full Text] [Related]
14. Osteoarticular disorders of renal origin: disease-related and iatrogenic.
Kay J; Bardin T
Baillieres Best Pract Res Clin Rheumatol; 2000 Jun; 14(2):285-305. PubMed ID: 10925746
[TBL] [Abstract][Full Text] [Related]
15. Pathogenetic and diagnostic aspects of dialysis-related amyloidosis.
Schaeffer J; Floege J; Ehlerding G; Koch KM
Nephrol Dial Transplant; 1995; 10 Suppl 3():4-8. PubMed ID: 7494614
[TBL] [Abstract][Full Text] [Related]
16. Beta 2-microglobulin amyloidosis in hemodialysis patients. An autopsy study of intervertebral disks and posterior longitudinal ligaments.
Honda K; Hara M; Ogura Y; Nihei H; Mimura N
Acta Pathol Jpn; 1990 Nov; 40(11):820-6. PubMed ID: 2127652
[TBL] [Abstract][Full Text] [Related]
17. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure.
Miyata T
Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608
[TBL] [Abstract][Full Text] [Related]
18. Dialysis-related amyloidosis: late finding or hidden epidemic?
Dember LM; Jaber BL
Semin Dial; 2006; 19(2):105-9. PubMed ID: 16551286
[TBL] [Abstract][Full Text] [Related]
19. [Rheumatologic and radiologic symptoms of dialysis-associated beta 2-microglobulin amyloidosis: long-term retrospective study of 175 chronic hemodialysis patients].
Hermann E; Mayet WJ; Wandel E; Scherer G; Schadmand S; Klose KJ; Poralla T; Meyer zum Büschenfelde KH; Köhler H
Z Rheumatol; 1991; 50(3):160-7. PubMed ID: 1927061
[TBL] [Abstract][Full Text] [Related]
20. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts.
Owen WF; Hou FF; Stuart RO; Kay J; Boyce J; Chertow GM; Schmidt AM
Kidney Int; 1998 May; 53(5):1365-73. PubMed ID: 9573554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
